【摘要】 目的研究老年心房颤动(房颤)患者采用达比加群酯联合参松养心胶囊治疗的效果和安全性。方法 60例老年房颤患者作为研究对象,根据患者的入院顺序分成观察组与对照组,各30例。对照组予以单一达比加群酯治疗,观察组在对照组的基础上联合参松养心胶囊治疗。对比两组患者的临床疗效及安全性。结果观察组患者的不良事件发生率为10.00%,低于对照组的33.33%,差异有统计学意义(P<0.05)。观察组患者的总有效率为93.33%,高于对照组的73.33%,差异有统计学意义(P<0.05)。结论采用达比加群酯联合参松养心胶囊治疗老年房颤可取得更为理想的治疗效果,且安全性更高,提倡在临床推广应用。更多还原

【Abstract】 Objective To study the effect and safety of dabigatran etexilate combined with Shensong Yangxin Capsule in the treatment of elderly patients with atrial fibrillation. Methods A total of 60 elderly patients with atrial fibrillation as study subjecst were divided into observation group and control group by admission order, with 30 cases in each group. The control group was treated by dabigatran etexilate, and the observation group was treated by Shensong Yangxin Capsule on the basis of the control group. The clinical efficacy and safety was compared between the two groups. Results The incidence of adverse events of the observation group was 10.00%, which was lower than that of the control group 33.33%, and the difference was statistically significant(P<0.05). The total effective rate of the observation group was 93.33%, which was higher than that of the control group 73.33%, and the difference was statistically significant(P<0.05). Conclusion Dabigatran etexilate combined with Shensong Yangxin Capsule shows ideal therapeutic effect for elderly patients with atrial fibrillation with high safety, and it is recommended to be promoted in clinical practice.更多还原